Home Cart Sign in  
Chemical Structure| 630420-16-5 Chemical Structure| 630420-16-5

Structure of Asunaprevir
CAS No.: 630420-16-5

Chemical Structure| 630420-16-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Asunaprevir is an inhibitor of hepatitis C virus (HCV) NS3 protease.

Synonyms: BMS-650032

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Asunaprevir

CAS No. :630420-16-5
Formula : C35H46ClN5O9S
M.W : 748.29
SMILES Code : ClC1=CC=C2C(C(O[C@H]3CN(C([C@@H](NC(OC(C)(C)C)=O)C(C)(C)C)=O)[C@H](C(N[C@@]4(C(NS(C5CC5)(=O)=O)=O)[C@H](C=C)C4)=O)C3)=NC=C2OC)=C1
Synonyms :
BMS-650032
MDL No. :MFCD27987900

Safety of Asunaprevir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7.5.1 cells 25 nM 72 hours To evaluate the effect of miRNAs on HCV infection, found that miR-25, let-7a, and miR-130a significantly inhibit HCV infection PMC5702611
E. coli cells 75 µM 3 hours To evaluate the inhibitory effect of asunaprevir on HCV protease activity, results showed that asunaprevir significantly inhibited HCV protease activity. PMC4215169
HEK293T cells >50 nM 24 hours To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC7063486
PBMC 300 ng/mL 10 hours To assess NK cell responsiveness to IFN α PMC6886885

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Healthy rats Intravenous injection 5 mg/kg Single dose To evaluate the effect of asunaprevir on gadoxetate hepatic transporter-mediated drug-drug interactions PMC10057977

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01019070 Hepatic Insufficiency PHASE1 COMPLETED 2025-08-11 Advanced Clinical Res Inst, An... More >>aheim, California, 92801, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT01886599 Hepatitis C PHASE1 COMPLETED 2025-02-13 Orlando Clinical Research Cent... More >>er, Orlando, Florida, 32809, United States|Davita Clinical Research, Minneapolis, Minnesota, 55404, United States|New Orleans Center For Clinical Research, Knoxville, Tennessee, 37920, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.34mL

0.27mL

0.13mL

6.68mL

1.34mL

0.67mL

13.36mL

2.67mL

1.34mL

References

 

Historical Records

Categories